5 Key Takeaways

• 1

  Age-related macular degeneration and diabetic retinopathy are leading causes of blindness, prompting significant advancements in retinal treatments.

• 2

  Intravitreal anti-VEGF injections, including bevacizumab and aflibercept, are crucial for managing abnormal blood vessel growth in retinal diseases.

• 3

  Emerging treatments for dry AMD include complement system inhibitors like pegcetacoplan and avacincaptad pegol, offering new hope for patients.

• 4

  Intravitreal implants provide sustained drug release, improving long-term management of conditions like diabetic macular edema with less frequent dosing.

• 5

  Port-delivery systems and gene therapies represent innovative approaches in retinal treatment, aiming to enhance patient outcomes and reduce injection frequency.